The Board and I are committed to maintaining the highest standards of corporate governance, integrity and ethics, which is embedded in our corporate culture and values. Our corporate governance structures support the effective delivery of Mediclinic’s strategy and are focused on maintaining and building a sustainable business and supporting our commitment to be a responsible corporate citizen in every country and community in which the Group does business. The key elements of our governance structures include:
- ensuring good clinical outcomes and quality healthcare (refer to the Clinical Services Overview, as well as the Clinical Services Report);
- upholding strict principles of corporate governance, integrity and ethics (refer to the Corporate Governance Statement);
- maintaining effective risk management and internal controls (refer to the report on Risk Management Principal Risks and Uncertainties);
- engaging with our stakeholders and responding to their reasonable expectations (refer to the stakeholder engagement section in the Sustainable Development Report;
- managing our business in a sustainable manner (refer to the Sustainable Development Highlights, as well as the Sustainable Development Report; and
- offering our employees competitive remuneration packages based on the principles of fairness and affordability (refer to the Directors’ Remuneration Report, as well as the Sustainable Development Report.
In the Corporate Governance Statement that follows, feedback is given on the governance framework, Board meetings and the principal activities of the Board, the composition and diversity of the Board and measures to ensure the Board’s accountability to our stakeholders. Every Director demonstrated their commitment to Mediclinic throughout the year, through their meeting attendance and the high quality of their contributions at those meetings. I am pleased that the Board structure put in place following the Al Noor Combination in February 2016 has operated effectively. The internal self-evaluation of the Board conducted during the year did not raise any major areas requiring improvement. With the retirement of Craig Tingle, Chief Financial Officer, and Ian Tyler, Senior Independent Director, during the year, the Nomination Committee and the Board continued to focus on succession planning and targeting diverse pools of talent from which to recruit the right individuals.
I remain confident that the Board, supported by an effective management team and an effective governance structure, is well placed to continue creating long-term value for stakeholders and maintaining Mediclinic’s leading position in the international healthcare market.
Dr Edwin Hertzog